Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
49 hedge funds and large institutions have $69.8M invested in Strongbridge Biopharma plc. in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 24 reducing their positions, and 15 closing their positions.
329% more call options, than puts
Call options by funds: $283K | Put options by funds: $66K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less funds holding
Funds holding: 59 → 49 (-10)
33% less capital invested
Capital invested by funds: $104M → $69.8M (-$34.3M)
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
67% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.76M |
| 2 |
Man Group
London,
United Kingdom
|
+$2.29M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$877K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$490K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$274K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.21M |
| 2 |
E
Ergoteles
New York
|
-$2.19M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.2M |
| 4 |
Goldman Sachs
New York
|
-$479K |
| 5 |
CAC
Cowen and Company
New York
|
-$459K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
51
Boothbay Fund Management
New York
| – | -$426K | -143,577 | Closed |
|
52
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$107K | -36,160 | Closed |
|
53
Charles Schwab
San Francisco,
California
| – | -$87K | -29,233 | Closed |
|
|
LP
54
LMR Partners
London,
United Kingdom
| – | -$62K | -20,742 | Closed |
|
55
Citadel Advisors
Miami,
Florida
| – | -$58K | -19,499 | Closed |
|
56
Two Sigma Investments
New York
| – | -$48K | -16,300 | Closed |
|
57
Prudential Financial
Newark,
New Jersey
| – | -$32K | -10,904 | Closed |
|
|
TSS
58
Two Sigma Securities
New York
| – | -$31K | -10,511 | Closed |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| – | -$11K | -3,657 | Closed |
|
|
PAM
60
Panagora Asset Management
Boston,
Massachusetts
| – | -$7K | -2,309 | Closed |
|
61
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$4K | -1,188 | Closed |
|
62
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -379 | Closed |
|
63
Osaic Holdings
Scottsdale,
Arizona
| – | +$23 | +10 | New |
|
SBBP Hedge Fund Activity: Q3 2021 in Review
49 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q3 2021, worth a combined $69.8M — down 33% from $104M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SBBP and 5 opened new positions — a net loss of 10 holders — while 24 trimmed existing stakes and 8 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.76M. The largest seller was OrbiMed, cutting an estimated $2.21M.
- 49 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q3 2021, down from 59 in Q2 2021.
- Funds reported $69.8M of Strongbridge Biopharma plc. stock for Q3 2021, down 33% quarter-over-quarter.
- 5 funds opened new Strongbridge Biopharma plc. positions in Q3 2021 and 15 closed out, a net change of -10 holders.
- The largest Strongbridge Biopharma plc. buyer in Q3 2021 was Stonepine Capital Management, an estimated $2.76M added.
- The largest Strongbridge Biopharma plc. seller in Q3 2021 was OrbiMed, an estimated $2.21M sold.
Based on aggregated 13F filings for Q3 2021.